As most of the benefit from aromatase inhibitor was seen in this period, the reduction in any recurrence with aromatase inhibitor was larger and more highly significant.
← all excerpts
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
1
—
—